LivaNova reported record second-quarter revenue and earnings per share and raised its full-year 2026 outlook. Revenue rose 9.8% on a constant currency basis to $391 million, with Cardiopulmonary revenue up 10% to $222 million and Epilepsy revenue up 10%. The company now expects full-year revenue growth of 8% to 9%, up from 7% to 8%, and adjusted diluted earnings per share of $4.30 to $4.40, up from prior guidance. LivaNova also announced a long-term supply agreement with Thermo Fisher Scientific for a critical oxygenator component and said it expects to submit a PMA supplement for its next-generation OSA system between the second half of 2026 and the first half of 2027.
LivaNova PLCRecord Q2 revenue and EPS, raised FY2026 guidance
Thermo Fisher Scientific IncSupply agreement with LivaNova for oxygenator component
ARKO Petroleum Corp.